ImaRx Therapeutics, Inc.’s (IRMX) Core Product Acquired by Microbix Biosystems
ImaRx Therapeutics, Inc. (NASD: IMRX) has recently signed a letter of intent stating that Microbix Biosystems will acquire urokinase inventory and related company assets from ImaRx for $17 million in cash. Urokinase, an FDA-approved thrombolytic, is a treatment for acute massive pulmonary embolism. It has been commercialized for more than 20 years and has been used on more than 4 million patients. Since 2006, ImaRx has been selling urokinase for medical purposes since they acquired a four-year inventory of the product from Abbott Laboratories. The company's stock rose 154.62% on Wednesday. The terms of the agreement state that Microbix will…
